Switchpoint Bio exits stealth with €4.75M to profile disease from blood
What's the deal? Switchpoint BioDealroom has a profile for this one. Try Dealroom →, a TechBio startup based in Helsinki and Cambridge, Massachusetts, has raised €4.75 million ($5.3 million) in a pre-Seed round to build a blood-based epigenomic platform for drug developers. Treehouse Delmar Investments led, with a €4.48 million investment.
What's the endgame? The company uses targeted DNA-methylation profiling to read epigenomic marks carried by circulating immune cells. The goal is to show drug developers which patients respond to a treatment, which do not, and why — from a routine blood sample, tracked over time.
Why now? Switchpoint emerged from stealth earlier this year and is moving from platform development into clinical and industry validation. Its first target is systemic lupus erythematosus, with other autoimmune diseases in view.
The startup was founded in 2025 by Samuel Myllykangas, who previously built Blueprint Genetics before its acquisition by Quest DiagnosticsDealroom has a profile for this one. Try Dealroom → in 2020, and Jason Buenrostro, a Harvard professor and inventor of the ATAC-seq profiling technology. Three co-founders joined them across commercial, technical, and scientific roles.
What could go wrong? The round backs early platform development, but Switchpoint has yet to prove its signals can reliably predict treatment response or sell to biopharma partners. "Our goal is to make these biological switchpoints visible from a routine blood sample, repeatedly and at the scale required for drug development," said Myllykangas, chief executive officer.
The capital will fund continued validation, expand clinical and biobank datasets, develop the epigenomic and AI platform, and grow the team across Helsinki and Cambridge.
The signal: Blood-based immune profiling is drawing fresh money as a tool for drug development — London-based IMU Biosciences raised more than $53 million this year to scale a rival approach. Switchpoint's €4.75 million ranks near the 96th percentile for health rounds in Finland, a notable early bet on turning epigenomics into evidence biopharma can use.
Read more: EU-Startups
Image credit: Generated with Gemini
